# Study of PlasmaCap IG in Adults and Children With PIDD

> **NCT03238079** · PHASE3 · UNKNOWN · sponsor: **Evolve Biologics** · enrollment: 74 (estimated)

## Conditions studied

- Primary Immune Deficiency Diseases (PIDD)

## Interventions

- **BIOLOGICAL:** 10% IGIV

## Key facts

- **NCT ID:** NCT03238079
- **Lead sponsor:** Evolve Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-05
- **Primary completion:** 2020-08-25
- **Final completion:** 2020-12-30
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238079, "Study of PlasmaCap IG in Adults and Children With PIDD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03238079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*